Pharmacokinetics of betamethasone in twin and singleton pregnancy

Praveen Ballabh, E. S. Lo, J. Kumari, T. B. Cooper, I. Zervoudakis, P. A M Auld, A. N. Krauss

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: The aims of the study were to compare the pharmacokinetics of betamethasone in singleton pregnancy with the pharmacokinetics in twin pregnancy and to assess the adrenal suppression produced by betamethasone. Study Design: We measured serial betamethasone and cortisol levels in 30 singleton and 21 twin pregnancies after the first dose of betamethasone and calculated the pharmacokinetic parameters for betamethasone including volume of distribution, half-life, and clearance. We also measured cord and maternal blood levels of betamethasone at the birth of infants of 13 singleton and 9 twin pregnancies. Results: The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 ± 2.4 versus 9.0 ± 2.7 hours; P < .017). Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 ± 6.4 versus 5.7 ± 3.1 L/h; P = .06) but did not reach statistical significance. Volume of distribution was similar in the two groups. Because the time between the last dose of betamethasone and birth varied widely (range, 2-158 hours), mothers with a longer interval after treatment tended to have a higher cord-to-maternal betamethasone ratio than did mothers with a shorter interval in both twin and singleton pregnancies. This finding indicated delayed fetal clearance, but the correlation was weak (R2 = 0.29 for twins and 0.08 for singletons). Conclusion: The shorter half-life of betamethasone in twin pregnancy than in singleton pregnancy may cause the level of betamethasone to be subtherapeutic for lung maturation in twin pregnancy.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume71
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Betamethasone
Twin Pregnancy
Pharmacokinetics
Mothers
Half-Life
Pregnancy
Parturition
Fetal Blood
Hydrocortisone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ballabh, P., Lo, E. S., Kumari, J., Cooper, T. B., Zervoudakis, I., Auld, P. A. M., & Krauss, A. N. (2002). Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clinical Pharmacology and Therapeutics, 71(1), 39-45. https://doi.org/10.1067/mcp.2002.120250

Pharmacokinetics of betamethasone in twin and singleton pregnancy. / Ballabh, Praveen; Lo, E. S.; Kumari, J.; Cooper, T. B.; Zervoudakis, I.; Auld, P. A M; Krauss, A. N.

In: Clinical Pharmacology and Therapeutics, Vol. 71, No. 1, 2002, p. 39-45.

Research output: Contribution to journalArticle

Ballabh, P, Lo, ES, Kumari, J, Cooper, TB, Zervoudakis, I, Auld, PAM & Krauss, AN 2002, 'Pharmacokinetics of betamethasone in twin and singleton pregnancy', Clinical Pharmacology and Therapeutics, vol. 71, no. 1, pp. 39-45. https://doi.org/10.1067/mcp.2002.120250
Ballabh, Praveen ; Lo, E. S. ; Kumari, J. ; Cooper, T. B. ; Zervoudakis, I. ; Auld, P. A M ; Krauss, A. N. / Pharmacokinetics of betamethasone in twin and singleton pregnancy. In: Clinical Pharmacology and Therapeutics. 2002 ; Vol. 71, No. 1. pp. 39-45.
@article{d6a08e4e8a4f4740961b09aa5cf3e521,
title = "Pharmacokinetics of betamethasone in twin and singleton pregnancy",
abstract = "Objective: The aims of the study were to compare the pharmacokinetics of betamethasone in singleton pregnancy with the pharmacokinetics in twin pregnancy and to assess the adrenal suppression produced by betamethasone. Study Design: We measured serial betamethasone and cortisol levels in 30 singleton and 21 twin pregnancies after the first dose of betamethasone and calculated the pharmacokinetic parameters for betamethasone including volume of distribution, half-life, and clearance. We also measured cord and maternal blood levels of betamethasone at the birth of infants of 13 singleton and 9 twin pregnancies. Results: The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 ± 2.4 versus 9.0 ± 2.7 hours; P < .017). Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 ± 6.4 versus 5.7 ± 3.1 L/h; P = .06) but did not reach statistical significance. Volume of distribution was similar in the two groups. Because the time between the last dose of betamethasone and birth varied widely (range, 2-158 hours), mothers with a longer interval after treatment tended to have a higher cord-to-maternal betamethasone ratio than did mothers with a shorter interval in both twin and singleton pregnancies. This finding indicated delayed fetal clearance, but the correlation was weak (R2 = 0.29 for twins and 0.08 for singletons). Conclusion: The shorter half-life of betamethasone in twin pregnancy than in singleton pregnancy may cause the level of betamethasone to be subtherapeutic for lung maturation in twin pregnancy.",
author = "Praveen Ballabh and Lo, {E. S.} and J. Kumari and Cooper, {T. B.} and I. Zervoudakis and Auld, {P. A M} and Krauss, {A. N.}",
year = "2002",
doi = "10.1067/mcp.2002.120250",
language = "English (US)",
volume = "71",
pages = "39--45",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of betamethasone in twin and singleton pregnancy

AU - Ballabh, Praveen

AU - Lo, E. S.

AU - Kumari, J.

AU - Cooper, T. B.

AU - Zervoudakis, I.

AU - Auld, P. A M

AU - Krauss, A. N.

PY - 2002

Y1 - 2002

N2 - Objective: The aims of the study were to compare the pharmacokinetics of betamethasone in singleton pregnancy with the pharmacokinetics in twin pregnancy and to assess the adrenal suppression produced by betamethasone. Study Design: We measured serial betamethasone and cortisol levels in 30 singleton and 21 twin pregnancies after the first dose of betamethasone and calculated the pharmacokinetic parameters for betamethasone including volume of distribution, half-life, and clearance. We also measured cord and maternal blood levels of betamethasone at the birth of infants of 13 singleton and 9 twin pregnancies. Results: The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 ± 2.4 versus 9.0 ± 2.7 hours; P < .017). Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 ± 6.4 versus 5.7 ± 3.1 L/h; P = .06) but did not reach statistical significance. Volume of distribution was similar in the two groups. Because the time between the last dose of betamethasone and birth varied widely (range, 2-158 hours), mothers with a longer interval after treatment tended to have a higher cord-to-maternal betamethasone ratio than did mothers with a shorter interval in both twin and singleton pregnancies. This finding indicated delayed fetal clearance, but the correlation was weak (R2 = 0.29 for twins and 0.08 for singletons). Conclusion: The shorter half-life of betamethasone in twin pregnancy than in singleton pregnancy may cause the level of betamethasone to be subtherapeutic for lung maturation in twin pregnancy.

AB - Objective: The aims of the study were to compare the pharmacokinetics of betamethasone in singleton pregnancy with the pharmacokinetics in twin pregnancy and to assess the adrenal suppression produced by betamethasone. Study Design: We measured serial betamethasone and cortisol levels in 30 singleton and 21 twin pregnancies after the first dose of betamethasone and calculated the pharmacokinetic parameters for betamethasone including volume of distribution, half-life, and clearance. We also measured cord and maternal blood levels of betamethasone at the birth of infants of 13 singleton and 9 twin pregnancies. Results: The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 ± 2.4 versus 9.0 ± 2.7 hours; P < .017). Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 ± 6.4 versus 5.7 ± 3.1 L/h; P = .06) but did not reach statistical significance. Volume of distribution was similar in the two groups. Because the time between the last dose of betamethasone and birth varied widely (range, 2-158 hours), mothers with a longer interval after treatment tended to have a higher cord-to-maternal betamethasone ratio than did mothers with a shorter interval in both twin and singleton pregnancies. This finding indicated delayed fetal clearance, but the correlation was weak (R2 = 0.29 for twins and 0.08 for singletons). Conclusion: The shorter half-life of betamethasone in twin pregnancy than in singleton pregnancy may cause the level of betamethasone to be subtherapeutic for lung maturation in twin pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0036159435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036159435&partnerID=8YFLogxK

U2 - 10.1067/mcp.2002.120250

DO - 10.1067/mcp.2002.120250

M3 - Article

C2 - 11823756

AN - SCOPUS:0036159435

VL - 71

SP - 39

EP - 45

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -